Torrent Pharmaceuticals (TORNTPHARM) Share Price Falls 2.19% to Rs 4,895; Valuation and Peer Analysis in Focus

Torrent Pharmaceuticals Share Price fell to Rs 4,895 on 03 September 2026 at 12:49:14 PM IST, down 2.19% for the day. The stock was lower by Rs 109.4 from the previous close of Rs 5,004.4, while the company’s market capitalisation stood at Rs 1,88,622.52 crore.

The supplied data confirms the decline, but it does not identify a company-specific trigger. That means today’s move is best read through price action, valuation and industry positioning rather than any unverified reason. For market participants tracking the stock, the session shows a weak intraday structure: the open was also the day’s high, and the current price matched the day’s low.

This makes the stock notable not only because it is down on the day, but also because it belongs to the large-cap pharmaceutical space and trades at premium valuation multiples. At the same time, profitability ratios remain stronger than many industry benchmarks, so the current setup combines rich pricing with healthy historical returns.

Torrent Pharmaceuticals (TORNTPHARM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 4,895
Previous Close	Rs 5,004.4
Today's Move	-Rs 109.40 (-2.19%)
Open	Rs 5,048.55
High	Rs 5,048.55
Low	Rs 4,895
Turnover	Rs 1.08 crore
Market Capitalisation	Rs 1,88,622.52 crore
Market Cap Category	Large Cap

Torrent Pharmaceuticals Share Price Today reflects a clear slide through the session. The stock opened at Rs 5,048.55, which was also the intraday high, and then moved down to Rs 4,895, the day’s low and current price at the supplied snapshot.

Versus the previous close of Rs 5,004.4, the stock was down Rs 109.4, or 2.19%. That indicates the early opening strength did not hold. Turnover stood at Rs 1.08 crore, confirming active trading value during the move.

The technical snapshot adds context. The stock is below the 50-day moving average of Rs 4,945.51, but still above the 200-day moving average of Rs 4,447.92. RSI was 51.8, which places the momentum reading near the middle rather than at an extreme. Taken together, the available numbers point to short-term weakness inside a longer-term level that still sits above the 200-day average.

Torrent Pharmaceuticals (TORNTPHARM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,88,622.52 crore
P/E Ratio	87.28x
P/B Ratio	21.21x
ROE	26.76%
ROCE	19.27%
EPS	Rs 57.34
Book Value Per Share	Rs 235.97
Dividend Yield	0.76%

Torrent Pharmaceuticals fundamental analysis shows a mix that often draws attention during down sessions: strong return ratios alongside expensive valuation multiples. In other words, the stock is not merely reacting to a one-day fall; it is also being judged against the price investors are paying for earnings and net worth.

At a market cap of Rs 1,88,622.52 crore, the company sits firmly in the large-cap bracket. The stock trades at a P/E ratio of 87.28 and a P/B ratio of 21.21, both elevated on an absolute basis. Profitability is stronger, with ROE at 26.76% and ROCE at 19.27%.

EPS stands at Rs 57.34 and book value per share at Rs 235.97. Dividend yield is 0.76%. These figures do not explain today’s fall on their own, but they do show why valuation remains central when the stock comes under pressure.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	87.28x
Benchmark Median P/E	31.97x
Benchmark Average P/E	48.6x
Benchmark P/E Range	3.49x to 648.54x
Company P/B Ratio	21.21x
Benchmark Median P/B	2.87x
Benchmark Average P/B	4.35x
Company ROE	26.76%
Benchmark Median ROE	11.79%
Benchmark Average ROE	11.15%
Company ROCE	19.27%
Benchmark Median ROCE	13.63%
Benchmark Average ROCE	13.69%
Company Market Capitalisation	Rs 1,88,622.52 crore
Benchmark Median Market Cap	Rs 727.27 crore
Benchmark Average Market Cap	Rs 14,141.34 crore

The same-industry benchmark covers 201 companies in Pharmaceuticals & Drugs. Against that set, Torrent is clearly priced above typical valuation levels. Its P/E of 87.28 is well above the median of 31.97 and the average of 48.6. The stock’s P/B of 21.21 is also far above the median of 2.87 and average of 4.35.

Profitability, however, compares more favourably. ROE of 26.76% is ahead of the benchmark median of 11.79% and average of 11.15%. ROCE of 19.27% is also above the median of 13.63% and average of 13.69%.

Scale is another differentiator. The company’s market capitalisation of Rs 1,88,622.52 crore is far above the industry median of Rs 727.27 crore and average of Rs 14,141.34 crore, though below the benchmark maximum of Rs 4,63,179.62 crore. The sector picture therefore suggests a premium valuation attached to a large business with above-benchmark returns.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,63,179.62	38.34	5.36	14.85	19.11
Divi's Laboratories	DIVISLAB	2,43,301.95	83.79	13.88	16.19	21.51
Zydus Lifesciences	ZYDUSLIFE	1,16,114.43	25.44	4.26	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.87	3.25	11.83	16
Laurus Labs	LAURUSLABS	1,00,498.07	92.06	17.85	18.31	18.2

The peer set shows Torrent as a large pharma name with one of the richer valuations in the group. Sun Pharmaceutical Industries has the biggest market cap at Rs 4,63,179.62 crore, but much lower P/E and P/B ratios of 38.34 and 5.36. Divi's Laboratories is closer on valuation at 83.79 P/E and 13.88 P/B, though still below Torrent on both measures.

Zydus Lifesciences and Cipla trade at notably lower multiples, with P/E ratios of 25.44 and 33.87 respectively. Their P/B ratios of 4.26 and 3.25 are also much lower. Laurus Labs is one of the few peers with a higher P/E at 92.06, but its market cap is smaller at Rs 1,00,498.07 crore.

On profitability, Torrent’s ROE of 26.76% is above Sun Pharma, Divi’s, Zydus, Cipla and Laurus Labs. Its ROCE of 19.27% is close to Sun Pharma’s 19.11%, above Cipla’s 16 and Laurus Labs’ 18.2, but below Divi’s 21.51 and Zydus 21.39. That profile supports why the stock commands a premium, even if the valuation is demanding.

Why Investors Are Watching Torrent Pharmaceuticals

• The stock fell 2.19% to Rs 4,895, down Rs 109.4 from the previous close of Rs 5,004.4.
• The open at Rs 5,048.55 was also the day’s high, while Rs 4,895 marked the low and current price.
• P/E of 87.28 and P/B of 21.21 are well above industry median levels.
• ROE of 26.76% and ROCE of 19.27% remain above broader same-industry averages.
• Market capitalisation of Rs 1,88,622.52 crore keeps the company among the larger listed pharma names.

About Torrent Pharmaceuticals

Torrent Pharmaceuticals is listed in the Healthcare sector under Pharmaceuticals & Drugs. Based on the supplied market and peer data, it is one of the larger companies in the industry set. In the peer universe provided here, it sits below Sun Pharmaceutical Industries and Divi's Laboratories on market cap, but above Zydus Lifesciences, Cipla and Laurus Labs.

Track Torrent Pharmaceuticals Share Price on Univest

UseTorrent Pharmaceuticals (TORNTPHARM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, readers can track Torrent Pharmaceuticals Share Price through live price updates, valuation ratios, profitability metrics, sector benchmarks and peer comparisons. That gives context for a one-day move without forcing a recommendation.

Frequently Asked Questions

Why is Torrent Pharmaceuticals Share Price falling today?

Ans. Torrent Pharmaceuticals Share Price was down 2.19% at Rs 4,895, a decline of Rs 109.4 from the previous close of Rs 5,004.4. The supplied data confirms the fall, but it does not establish a company-specific catalyst.

What is Torrent Pharmaceuticals Share Price Today?

Ans. It stood at Rs 4,895 at the supplied snapshot time of 12:49:14 PM IST on 03 September 2026, versus the previous close of Rs 5,004.4. The stock moved 2.19% lower during the session.

How did the stock perform intraday today?

Ans. The stock opened at Rs 5,048.55, which was also the day’s high, and then declined to Rs 4,895, the day’s low and current price. That indicates weakness through the session rather than a recovery from lower levels.

What does the P/E ratio indicate?

Ans. The stock trades at a P/E of 87.28, compared with the same-industry median of 31.97 and average of 48.6. That places it at a premium valuation versus much of the Pharmaceuticals & Drugs benchmark universe.

How does the P/B ratio compare with the industry?

Ans. The company’s P/B ratio is 21.21, well above the industry median of 2.87 and average of 4.35. This suggests the market is assigning a substantial premium relative to book value.

Are the profitability ratios strong?

Ans. ROE stands at 26.76% and ROCE at 19.27%, both above the same-industry averages of 11.15% and 13.69% respectively. The relevant peer median ROE is 11.79%. The relevant peer median ROCE is 13.63%.

How does Torrent compare with major pharma peers?

Ans. Its P/E of 87.28 is higher than Sun Pharma, Zydus and Cipla, slightly above Divi's Laboratories, and below Laurus Labs. Its ROE of 26.76% is stronger than the supplied peers, while ROCE is mixed across the comparison set.

What should investors monitor next?

Ans. Investors may watch whether the stock holds around Rs 4,895 after slipping below the 50-day moving average of Rs 4,945.51, while still remaining above the 200-day moving average of Rs 4,447.92.